Open-label, 4-Part Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Alnuctamab (BMS-986349/CC-93269) in Participants With Moderate to Severe Refractory Systemic Lupus Erythematosus

This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

开始日期2026-03-01

申办/合作机构

Icahn School of Medicine at Mount Sinai

NCT06232707

/ Withdrawn临床3期

A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM

The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).

开始日期2024-05-03

申办/合作机构

Celgene Corp.

NCT06163898

/ Active, not recruiting临床1期

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.

开始日期2024-02-27

申办/合作机构

Celgene Corp.

100 项与 Alnuctamab 相关的临床结果

登录后查看更多信息

100 项与 Alnuctamab 相关的转化医学

登录后查看更多信息

100 项与 Alnuctamab 相关的专利（医药）

登录后查看更多信息

项与 Alnuctamab 相关的文献（医药）

2025-05-01·Clinical Lymphoma Myeloma & Leukemia

Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives

Review

作者: Rasche, Leo ; Einsele, Hermann ; Waldschmidt, Johannes M ; Kortüm, K Martin

Despite significant advancements, multiple myeloma (MM) remains incurable, and there is still a pressing need for new therapeutic strategies with highly selective mechanisms of action and balanced off-target toxicity. In recent years, the development of "off-the-shelf" bispecific antibodies (bsAbs) has significantly enhanced our ability to treat relapsed or refractory MM. Teclistamab, elranatamab (both BCMA × CD3), and talquetamab (GPRC5D × CD3) are approved for treating MM patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Meanwhile, the range of available bsAbs is rapidly expanding, offering patients and healthcare providers a broad selection of options that vary in target antigens, binding domains, construct designs, dosing regimens, and side effects. As linvoseltamab, alnuctamab, and ABBV-383 (all BCMA × CD3), as well as forimtamig (GPRC5D × CD3) and cevostamab (FcRH5 × CD3) progress through late-stage clinical development, emerging trispecific antibodies are now available that target either 2 different MM-associated antigens or provide additional co-stimulatory signals to prevent T-cell exhaustion. Despite this plethora of therapeutic options, resistance to bsAbs is an inevitability, and the optimal positioning of these drugs within the current MM treatment landscape remains to be determined. In this review, we examine the available data on all clinically accessible bsAbs, evaluating their potential, current limitations, and implications for efficacy and safety, with the aim of achieving deeper responses and longer overall survival for MM patients.

2024-09-01·CLINICAL PHARMACOLOGY & THERAPEUTICS

Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T‐Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis

Article

作者: Lamba, Manisha ; Hsu, Kevin ; Bar, Merav ; Gaudy, Allison ; Kiesel, Brian ; Godwin, Colin ; Osawa, Mayu ; Masilamani, Madhan ; Burgess, Michael

Alnuctamab, a B‐cell maturation antigen (BCMA)‐targeting T‐cell engager, has demonstrated encouraging antitumor activity in the phase I study CC‐93269‐MM‐001 treating patients with relapsed or refractory multiple myeloma. Identification of a recommended Phase III dose (RP3D) was a key objective, as such population pharmacokinetic (PopPK) and exposure–response analysis was critical. Intravenous (IV) alnuctamab was administered in fixed doses (0.15–10 mg) or in step‐up doses to a maximum 10‐mg target dose. Subcutaneous (SC) step‐up doses of 3 and 6 mg were followed by a target dose range of 10–60 mg. Concentration data from IV and SC alnuctamab administration was pooled and was well described by a two‐compartment PopPK model with first‐order absorption and elimination. Covariate analysis determined that the inclusion of baseline soluble BCMA (sBCMA) on clearance significantly improved model fitting. Individual exposure parameters were estimated from the final model to characterize exposure–response relationships. Switching from IV to SC administration improved the safety profile of alnuctamab by limiting the frequency of grade ≥2 CRS events. A significant exposure–CRS relationship was observed after the first SC dose, but not subsequent dose administrations. Exposure–safety analysis did not find a statistically significant relationship between increasing exposure and the probability of key safety events of interest. Logistic regression analysis for patients administered SC alnuctamab identified that increased exposure significantly increased the probability of response, although the additional benefit was minimal at exposures above 30 mg target dose. Considering the totality of exposure–response data, the clinical pharmacology assessment supported a SC RP3D of 3/6/30 mg.

2020-11-10·Oncotarget

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma

Article

作者: Mutis, Tuna ; Nijhof, Inger S. ; Broekmans, Marloes ; Maas-Bosman, Patricia W.C. ; Verkleij, Christie P.M. ; van de Donk, Niels W.C.J. ; Kruyswijk, Sandy ; Zweegman, Sonja ; Absalah, Saida ; Frerichs, Kristine A.

B-cell maturation antigen (BCMA)-targeting bispecific antibodies and bispecific T-cell engagers (BiTEs) redirect T-cells to BCMA-expressing multiple myeloma (MM) cells. These MM cells are subsequently eliminated via various mechanisms of action including the release of granzymes and perforins. Several phase 1, dose-escalation studies show pronounced activity of BCMA-targeting bispecific antibodies, including teclistamab, AMG420 and CC-93269, in heavily pretreated MM patients. Cytokine release syndrome is the most common adverse event, which can be adequately managed with tocilizumab or steroids. Several clinical trials are currently evaluating combination therapy with a BCMA-specific bispecific antibody, based on preclinical findings showing that immunomodulatory drugs or CD38-targeting antibodies enhance the activity of bispecific antibodies. In addition, bispecific antibodies, targeting other MM cell surface antigens (i. e. GPRC5D, CD38 and FcRH5), are also evaluated in early phase clinical trials. Such bispecific antibodies, targeting other antigens, may be given to patients with low baseline BCMA expression, disease with substantial heterogeneity in BCMA expression, following prior BCMA-targeted therapy, or combined with BCMA bispecific antibodies to prevent development of antigen escape.

项与 Alnuctamab 相关的新闻（医药）

2026-02-21

·展博血研通

Leukemia（IF13.4）| BCMA 靶向新药 ALNUC 皮下给药显优势！复发 / 难治性多发性骨髓瘤患者 CR 率超 35%，CRS 风险近零

导读为解决复发 / 难治性多发性骨髓瘤（RRMM）治疗中 BCMA 靶向疗法的毒性与给药问题，本研究开展 Ⅰ 期首次人体试验，纳入经≥3 线治疗的 RRMM 患者，对比 Alnuctamab（ALNUC）静脉（IV）与皮下（SC）给药的安全性和有效性，探索剂量递增方案与感染防控策略；结果显示 SC 给药安全性更优（3/4 级 CRS 发生率 0%），30mg 剂量组客观缓解率（ORR）达 71.4%，49.5% 患者 MRD 阴性，且低基线 sBCMA 水平与更长无进展生存期相关，证实 SC 给药联合逐步升剂量、后期减频方案在 RRMM 治疗中兼具疗效与安全性，为双特异性抗体研发提供新参考。注：该文章发表于《Leukemia》，最新影响因子为13.4，JCR分区为血液学Q1（7/98）和肿瘤学Q1（20/326），中科院医学1区。研究亮点创新采用 2+1 结构双特异性抗体设计，实现 BCMA 双价结合与 CD3 单价结合的精准靶向；首次证实皮下给药（SC）较静脉给药（IV）显著降低 CRS 风险（无 3/4 级 CRS）；建立 “逐步升剂量 + 后期减频” 给药方案，在保证疗效（30mg 组 ORR 71.4%）的同时降低感染等毒性，且发现基线 sBCMA 水平可作为疗效预测标志物。研究方法本研究为开放标签、剂量递增 / 扩展 Ⅰ 期临床试验（NCT03486067），纳入经≥3 线治疗（含蛋白酶体抑制剂、免疫调节药、抗 CD38 抗体）且 60 天内疾病进展的 RRMM 患者，排除既往 BCMA 靶向治疗史（IV 组 6 例除外）。ALNUC IV 给药剂量 0.15-10mg，按周期调整给药频率；SC 给药采用 3mg、6mg 逐步升剂量后，给予 10-60mg 目标剂量，后期调整为每 4 周一次。主要终点为安全性（不良事件、剂量限制性毒性等），次要终点包括 ORR、无进展生存期（PFS）等，通过 EuroFlow 检测微小残留病（MRD），采用 Luminex 平台分析细胞因子水平，运用 Kaplan-Meier 法进行生存分析，同时探索基线 sBCMA 水平等预测标志物。此外，制定针对性感染防控策略，包括免疫球蛋白替代、抗感染预防用药等。结果解读共 95 例患者接受 SC 给药，中位随访 11.8 个月，44.2% 患者仍在治疗。安全性方面，98.9% 患者出现治疗相关不良事件（TEAE），74.7% 为 3/4 级，最常见为中性粒细胞减少（43.2%）和感染（14.7%），CRS 发生率 57.9% 但均为 1-2 级，神经毒性罕见。疗效方面，全剂量组 ORR 58.9%，30mg 推荐剂量组 ORR 达 71.4%，全剂量组和 30mg 组完全缓解（CR）率均超 35%；49.5% 患者 MRD 阴性，30mg 组 MRD 阴性率 57.1%，CR 患者中 MRD 阴性率高达 88.2%-94.4%。药代动力学显示 ALNUC 呈线性药代特征，半衰期约 14 天，SC 给药细胞因子峰值延迟且水平更低。预后相关分析表明，基线 sBCMA≤中位数的患者 PFS 更长，12 个月 PFS 率达 59.78%，而 IV 给药因 3/4 级 CRS 发生率 7.1% 且 ORR 仅 40%，研究转向 SC 给药。 Figure 1：Alnuctamab 皮下给药（SC）的客观缓解率及缓解深度分布该图清晰呈现了 Alnuctamab 皮下给药在复发 / 难治性多发性骨髓瘤（RRMM）患者中的疗效响应情况，通过对比所有目标剂量组（n=95）与 30mg 推荐剂量组（n=49）的客观缓解率（ORR）及不同缓解深度（部分缓解 PR、非常好的部分缓解 VGPR、完全缓解 CR、严格完全缓解 sCR）的占比，直观展现了剂量与疗效的关联。结果显示，30mg 剂量组的 ORR（71.4%）显著高于全剂量组（58.9%），且缓解深度更优，30mg 组中≥VGPR 的患者占比达 53.1%、≥CR 的患者占比达 36.7%，均高于全剂量组的 46.3% 和 35.8%，证实 30mg 是兼顾疗效与安全性的最优剂量，且 Alnuctamab SC 能为经多线治疗的 RRMM 患者带来深度且有效的疾病缓解。 Figure 2：Alnuctamab 皮下给药（SC）的疗效持续性及无进展生存期（PFS）该图由患者疗效随时间变化曲线（A）和 PFS 生存曲线（B）两部分组成，核心阐明了 Alnuctamab SC 治疗 RRMM 的疗效持久性。图 A 显示，患者的治疗响应随时间推移逐渐加深，多数患者在治疗初期即达到 PR 及以上缓解，并持续维持，无明显早期疗效衰减；图 B 通过 Kaplan-Meier 生存分析展示，全剂量组的中位 PFS 为 11.54 个月，12 个月 PFS 率达 49.64%，而 30mg 剂量组的中位 PFS 未达到（95% CI：6.48 - 未评估），12 个月 PFS 率为 50.21%，且两组均有部分患者在随访超过 24 个月后仍保持无进展状态。这些数据印证了 Alnuctamab SC 治疗的长期有效性，尤其 30mg 剂量组能为患者提供更持久的疾病控制，支持其作为后续临床应用的推荐剂量。 Figure 3：基线可溶性 BCMA（sBCMA）水平与 Alnuctamab 皮下给药（SC）疗效的关联该图聚焦于疗效预测标志物的探索，明确了基线 sBCMA 水平对 Alnuctamab SC 治疗 RRMM 疗效的预测价值。图 A 通过对比不同剂量组中应答者（R）与非应答者（NR）的基线 sBCMA 水平，发现所有剂量组中应答者的基线 sBCMA 水平均显著低于非应答者（总体 p=0.000002），且 30mg 等核心剂量组中该差异同样显著（p=0.0009）；图 B 的 PFS 生存分析进一步证实，基线 sBCMA 水平≤中位数（全剂量组 161ng/mL、30mg 组 113ng/mL）的患者，其 PFS 显著长于 sBCMA 水平高于中位数的患者，其中 30mg 剂量组中低基线 sBCMA 患者的 12 个月 PFS 率（55.00%）远高于高基线水平患者（33.33%）。该结果表明，基线 sBCMA 水平可作为筛选 Alnuctamab SC 治疗获益人群的关键生物标志物，为临床个体化治疗决策提供依据。 Figure 4：Alnuctamab 静脉给药（IV）与皮下给药（SC）对炎症细胞因子水平的影响该图通过对比 Alnuctamab 两种给药方式下核心炎症细胞因子（IL-6、IL-10、颗粒酶 B、TNF-α）的动态变化，从机制层面解释了 SC 给药的安全性优势。结果显示，IV 给药后细胞因子水平在 6 小时即达到峰值，而 SC 给药的细胞因子峰值延迟至 48 小时，且峰值浓度显著低于 IV 给药：其中 IL-6（图 A）、IL-10（图 B）、颗粒酶 B（图 C）、TNF-α（图 D）的峰值水平均呈现 IV＞SC 的趋势。由于这些细胞因子（尤其是 IL-6）的过度、快速释放是细胞因子释放综合征（CRS）的核心发病机制，SC 给药导致的细胞因子 “延迟且低峰” 释放模式，能够有效避免免疫系统的过度激活，这也与临床中 SC 给药无 3/4 级 CRS 发生的安全性数据一致，从分子机制上验证了 SC 给药相较于 IV 给药的安全性优势。研究总结本 Ⅰ 期临床试验证实，Alnuctamab（ALNUC）皮下给药（SC）在经多线治疗的复发 / 难治性多发性骨髓瘤（RRMM）患者中具有优异的获益 - 风险比。SC 给药较静脉给药安全性显著提升，无 3/4 级细胞因子释放综合征（CRS）发生，感染等毒性可控；30mg 剂量组客观缓解率（ORR）达 71.4%，微小残留病（MRD）阴性率高，且 “逐步升剂量 + 后期减频” 方案兼顾疗效持续性与给药便利性。基线可溶性 BCMA（sBCMA）水平可作为疗效预测标志物，低水平患者预后更优。尽管该药物研发已终止，但研究证实的 SC 给药方式、剂量调整策略及毒性管理经验，为后续双特异性抗体等 T 细胞重定向疗法的研发提供了重要参考。局限性：为 Ⅰ 期试验，样本量有限且随访时间较短，缺乏与其他 BCMA 靶向疗法的头对头比较，长期疗效与安全性数据不足。展望：未来可基于本研究的剂量方案与给药方式，开展更大规模 Ⅲ 期临床试验；进一步探索 sBCMA 等标志物的临床应用价值，优化患者筛选；将相关给药策略与毒性管理经验应用于其他双特异性抗体研发，拓展 RRMM 治疗选择。文献来源：Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L, Namburi S, Ribas P, Santoro A, Rodriguez-Otero P, Creignou M, Chen J, Cao C, Kiesel B, Gaudy A, Thompson EG, Shen Y, Zarif S, Hsu K, Shelat SG, Burgess MR, Godwin C, Costa LJ. Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study. Leukemia. 2026 Jan 7. doi: 10.1038/s41375-025-02841-x. Epub ahead of print. PMID: 41501501. #复发难治性多发性骨髓瘤#Alnuctamab#BCMA靶向疗法#双特异性抗体#皮下给药#细胞因子释放综合征#微小残留病#无进展生存期本文中使用的图片来源于Pubmed，因客观原因未能与权利人取得联系。本平台出于学术交流目的引用，无意侵犯原作者权益。如权利人认为不妥，请及时联系公众号后台，我们将立即删除或协商解决。医学国自然，省自然，博士课题设计，医学实验外包，医学SCI，实验方案设计,免费的线上博导一对一沟通，确认实力后再谈合作，科研合作可以加微信：SCI971SCI 国家杰青一对一答疑视频博士课题设计专家答疑，如何从亚专业中选取更适合的方向医学国自然面上项目专家答疑实况，解决申请过程中的任何问题医学省自然申请答疑，立项的关键条件是哪一些？从哪些方向可以杀出重围国家科技重大专项，专家一对一指导方案设计实录临床型博士如何准备国青标书？没有预实验怎么办？专家一对一解答规划 #医学科研#国自然#医学博士#医学国自然#医生科研信息合集高分文献解析国自然中标标书分享国自然中标信息医学硕博论文解析急诊重症科研分享耳鼻喉科研分享肾内科科研分享麻醉领域科研分享中医药科研研究

2025-03-10

·医药地理

NMPA批准辉瑞CD3/BCMA双抗获批上市

3月10日，辉瑞宣布CD3/BCMA双抗埃纳妥单抗（Elranatamab，商品名：易瑞欧）获国家药监局附条件批准上市，用于治疗既往接受过至少三种治疗（含一种蛋白酶体抑制剂、一种免疫调节剂和一种抗CD38单克隆抗体）的复发或难治性多发性骨髓瘤（R/R MM）成人患者。此次批准主要是基于单臂II期MagnetisMM-3研究以及中国单独的Ib/II期单臂研究MagnetisMM-8研究的积极数据。MagnetisMM-3研究结果显示，接受过多线治疗的R/R MM患者接受埃纳妥单抗治疗后，中位总生存期（mOS）为24.6个月，中位无进展生存期（mPFS）为17.2个月。此外，中位随访33.9个月时，患者的中位缓解持续时间（mDOR）仍未达到，DOR达到30个月的患者比例为61.0%。目前，全球共两款CD3/BCMA双抗获批上市，另一款为强生的特立妥单抗（商品名：泰立珂），该药物已于2024年6月在中国获批上市。此外，再生元的linvoseltamab已在欧美申报上市，还有艾伯维的Etentamig（TNB-383B）和BMS的Alnuctamab已进入III期阶段。 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

上市批准临床3期临床2期

2024-12-16

·FierceBiotech

BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Century, Immatics

Under CEO Boerner, BMS continues to peel back a string of deals made under former leader Caforio\'s leadership.\n Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid \"ongoing portfolio prioritization efforts” within the Big Pharma, one of the affected companies revealed in an SEC document.The cuts were disclosed in separate Securities and Exchange Commission (SEC) filings made by Century Therapeutics and Immatics.Philadelphia-based Century had entered a collaboration with BMS back in 2022 in which the partners were working to develop stem cell-derived, engineered natural killer cell and gamma delta T cell candidates for blood cancers. The Big Pharma paid out $150 million in cash and an equity investment, plus committed more than $3 billion in biobucks.Now, after reviewing its portfolio, BMS is terminating the entire deal “without cause,” according to an SEC document filed Dec. 12. The dissolution is effective March 12, 2025.The programs have stayed in discovery and early-preclinical stages, with Century “encouraged by the scientific progress on the programs,” according to the SEC document. The biotech, which is currently conducting a strategic review of its preclinical pipeline, said it will assess potential opportunities for the programs in acute myeloid leukemia and multiple myeloma.The termination is “disappointing, but okay,” analysts from Leerink Partners wrote in a Dec. 13 note. The BMS decision doesn’t change the analysts\' positive long-term view of Century’s cell therapy platform or lead program, a CD19-targeting autoimmune candidate in phase 1 testing, the Leerink team noted. Given the partial focus on multiple myeloma, the Leerink Partners team wrote that the termination may reflect BMS’ acknowledgement that competitive hurdles in the indication are too high to warrant significant investments in the space. Because of that, the Leerink analysts don\'t assume the termination indicates anything negative about Century’s platform.The reprioritization at the Big Pharma, while “unfortunate,” is consistent with recent pipeline decisions made under CEO Chris Boerner, Ph.D.—who replaced Giovanni Caforio, M.D., last year—that indicate “more judicious resource allocation on oncology assets,” Leerink\'s analysts wrote.Since Boerner has taken the reins, BMS has also dropped a deal related to Agenus’ TIGIT bispecific antibody and an agreement with Eisai for its antibody drug conjugate (ADC).German biotech Immatics can now be added to that list, too. BMS inked a deal related to Immatics’ T-cell engager development in 2022—an expansion of a 2019 pact that focused on an autologous T cell receptor-based therapy (TCR-T). The revised deal included multiple off-the-shelf TCR-T and CAR-T programs, plus an upfront payment of $60 million and the chance to make up to $700 million per program through milestone and royalty payments.In 2023, BMS expanded the deal once again, exercising an option on an unnamed TCR-T.The two pact expansions have now been discarded, effective March 12 of next year, according to Dec. 13 SEC documents. The initial 2019 agreement remains intact. Earlier this year, BMS also jettisoned a bispecific molecule it licensed from Immatics for $150 million upfront in late 2021.The Big Pharma has also discontinued two internal multiple myeloma programs this year, including a phase 3-ready BCMA bispecific called alnuctamab because the company’s “business objectives” changed and a latestage BCMA CAR-T due to slow patient enrollment.

细胞疗法抗体药物偶联物免疫疗法引进/卖出临床1期

100 项与 Alnuctamab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多发性骨髓瘤	临床3期	中国	Celgene Corp.	2024-05-03
多发性骨髓瘤	临床3期	日本	Celgene Corp.	2024-05-03
多发性骨髓瘤	临床3期	阿根廷	Celgene Corp.	2024-05-03
多发性骨髓瘤	临床3期	澳大利亚	Celgene Corp.	2024-05-03
多发性骨髓瘤	临床3期	奥地利	Celgene Corp.	2024-05-03
多发性骨髓瘤	临床3期	比利时	Celgene Corp.	2024-05-03
多发性骨髓瘤	临床3期	巴西	Celgene Corp.	2024-05-03
多发性骨髓瘤	临床3期	加拿大	Celgene Corp.	2024-05-03
多发性骨髓瘤	临床3期	智利	Celgene Corp.	2024-05-03
多发性骨髓瘤	临床3期	捷克	Celgene Corp.	2024-05-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06232707 (ALUMMINATE RRMM, EHA2024)	临床3期	复发性多发性骨髓瘤	466	Alnuctamab	繭構願觸遞壓鑰鹽築夢(鑰選艱網糧鏇廠獵願襯) = 選鬱鬱壓願醖築蓋製糧餘鏇廠網網網齋鑰餘鬱 (壓遞蓋簾網憲願蓋衊顧 ) 更多	积极	2024-05-14
NCT03486067 (Phase 1 First‑in‑Human Clinical Study, ASH2023)	临床1期	复发性多发性骨髓瘤	73	ALNUC (BMS-986349; CC-93269)	鏇鑰築選觸繭範製觸艱(築糧觸遞遞鬱積衊艱齋) = 糧憲顧衊鏇夢製鏇繭鏇醖獵憲醖蓋鏇廠衊遞鹽 (遞艱築遞構觸齋淵簾簾 ) 更多	-	2023-12-09
ASH2023	N/A	多发性骨髓瘤	1,926	BCMA-directed BsAbs	夢簾獵願願衊築築糧窪(衊廠獵選衊顧觸壓選獵) = 鏇製襯鹹襯艱鬱願蓋壓鏇廠醖範淵膚製築蓋壓 (夢網鏇壓夢繭衊餘廠齋 ) 更多	-	2023-12-09
NCT03486067 (EHA2023)	临床1期	复发性多发性骨髓瘤	70	ALNUCTAMAB	餘積遞蓋積襯築簾範襯(顧憲繭淵獵醖鑰襯壓選) = Any-G/G3-4 treatment-emergent adverse events (TEAEs) occurred in 99%/79% of SC pts; most common were CRS (56%/0%), neutropenia (49%/42%), infections (47%/10%), anemia (41%/25%), and thrombocytopenia (33%/14%) 鏇獵壓築積願鏇衊憲觸 (窪構鹹築製艱觸鏇夢衊 ) 更多	-	2023-06-08
NCT03486067 (EHA2023)	临床1期	复发性多发性骨髓瘤	-	IV ALNUC	繭醖構衊願窪獵醖觸積(願獵艱襯鑰壓積襯鬱鹽) = 遞網壓膚獵顧鹹積餘鏇淵鹽襯蓋醖鹽遞簾鹽壓 (齋遞憲齋選遞淵蓋餘遞 )	-	2023-06-08
NCT03486067 (ASH 12022 \| ASH 22022) 人工标引	临床1期	复发性多发性骨髓瘤	70	Alnuctamab	鏇遞選鹽廠襯觸憲窪淵(網鑰鏇築遞膚鬱窪淵選) = 範艱憲願衊簾壓網簾築糧糧糧衊糧蓋製餘壓鬱 (襯選願製襯夢憲製鬱鏇 ) 更多	积极	2022-11-15
NCT03486067 (EHA2020)	临床1期	复发性多发性骨髓瘤	30	CC-93269	選夢廠淵觸繭築憲遞糧(廠築築積鬱積憲積鹹鑰) = CRS was reported in 23 (77%) pts, the majority of whom reported a maximum grade 1 (n=15 [50%]) or grade 2 (n=7 [23%]), and occurred most frequently with the first or second dose (n=30 of 37 events [81%]) 襯膚窪夢醖壓製選構願 (顧壓鹹鹹簾廠鑰築獵獵 ) 更多	积极	2020-05-14